What are the trends and in-hospital outcomes of catheter ablation for atrial fibrillation in patients with myeloproliferative neoplasms?

Clicks: 1
ID: 323286
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #148 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Catheter ablation is the standard of care for symptomatic atrial fibrillation, yet safety and efficacy in patients with myeloproliferative neoplasms (MPNs), a class of hematologic malignancies conferring prothrombotic and inflammatory phenotypes, remains understudied. Methods We analyzed the National Inpatient Sample (2016-2022), representing 280,450 adult patients undergoing catheter ablation for atrial fibrillation across 147 strata and 17,330 primary sampling units. We identified MPN patients using ICD-10 diagnosis and employed multivariate logistic regression adjusting for 24 covariates including demographics, charlson comorbidity index, and hospital characteristics to assess in-hospital mortality and complications. Results 1,070 of the catheter ablation patients identified were MPN patients (381.5 per 100,000 ablations). In-hospital mortality rates were comparable between MPN and non-MPN cohorts (0.93% vs. 1.11%, adjusted OR 0.58, 95% CI: 0.14-2.39, p=0.451). While unadjusted analysis revealed elevated acute kidney injury (AKI) in MPN patients (27.1% vs. 21.0%, p=0.027), this association was attenuated after multivariable adjustment (adjusted OR 1.21, 95% CI: 0.84-1.75, p=0.294). MPN status independently predicted longer hospital length of stay (+1.5 days, p=0.026). No significant differences emerged in major bleeding (1.4% vs. 1.7%), cardiac tamponade (0.5% vs. 1.3%), stroke (2.3% vs. 1.4%), or major adverse cardiac events. Temporal trend analysis from 2016-2022 demonstrated stable MPN prevalence (p=0.949) with no significant interaction between MPN status and year for mortality outcomes (p=0.668). Conclusions Catheter ablation for atrial fibrillation in MPN patients achieves mortality rates comparable to the general population undergoing ablation, with AKI representing the primary area of heightened vigilance. The results of our study support the procedural safety of catheter ablation in selected MPN patients. These findings identify a base for standardized cardio-oncology protocols addressing arrhythmia management in patients with MPN and other hematologic malignancies.
Reference Key
openalex_W7172349534 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors A Bolad, M Elganainy, I Motairek, F Alenezi, I Bolad
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.145
URL
https://doi.org/10.1093/eurheartjsupp/suag097.145
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.